These include certain antipsychotics (olanzapine, quetiapine, risperidone), mood stabilizers (lithium, valproate), some antidepressants (mirtazapine, paroxetine, amitriptyline), corticosteroids (prednisone), certain diabetes medications (insulin, sulfonylureas, thiazolidinediones), some beta-blockers (propranolol, metoprolol), and anticonvulsants (gabapentin, pregabalin)
If you want specific sources to read, check the New England Journal of Medicine trial on GLP1 agents for metabolic outcomes, the 2024 JAMA Internal Medicine paper on semaglutide and mental health, the 2024 Scientific Reports analysis, and recent reviews by regulatory agencies and psychiatry meetings that discuss case reports and signal detection
Effect of liraglutide on cardiovascular outcomes in elderly patients: a post hoc analysis of a randomized controlled trial
Medicinal prospects of antioxidants: A review
However, its potential impact on sleep, particularly insomnia, has become a topic of increasing interest and concern